Role of basal inflammatory status as a predictor of survival in bevacizumab-treated advanced non-small cell lung cancer (NSCLC) patients.

被引：0
|
作者：
Botta, C.
Guglielmo, A.
Bestoso, E.
Apollinari, S.
Licchetta, A.
Blardi, P.
Tassone, P.
Chiriaco, G.
Barbieri, V.
Mantovani, G.
Tagliaferri, P.
Correale, P.
机构：
[1] Siena Univ Hosp, Ist Toscano Tumori, Med Oncol Unit, Dept Oncol, Siena, Italy
[2] Sect Med Oncol, Siena, Italy
[3] Siena Univ Hosp, Dept Clin Pharmacol, Siena, Italy
[4] Univ Catanzaro, Sch Med, Sect Med Oncol, Catanzaro, Italy
[5] Magna Graecia Univ Catanzaro, Med Oncol Unit, Catanzaro, Italy
[6] Tommaso Campanella Canc Ctr, Catanzaro, Italy
[7] Univ Cagliari, Dept Med Oncol, Cagliari, Italy
[8] Siena Univ Hosp, Dept Oncol, Med Oncol Unit, Siena, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.7582
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7582
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Targeted therapy of advanced non-small cell lung cancer: the role of bevacizumab
    Stinchcombe, Thomas E.
    BIOLOGICS-TARGETS & THERAPY, 2007, 1 (03): : 185 - 194
  • [22] The role of inflammatory biomarkers in advanced non-small cell lung cancer patients treated with chemo-immunotherapy
    Zattarin, E.
    Manglaviti, S.
    Galli, E.
    Apollonio, G.
    Beninato, T.
    Mazzeo, L.
    Massa, G.
    Bottiglieri, A.
    Ganzinelli, M.
    Proto, C.
    Ferrara, R.
    Prelaj, A.
    Galli, G.
    De Toma, A.
    Brambilla, M.
    Occhipinti, M.
    Garassino, M. C. C.
    De Braud, F. G. M.
    Lo Russo, G.
    ANNALS OF ONCOLOGY, 2021, 32 : S1010 - S1011
  • [23] Physiological correlates of cancer-related fatigue in advanced non-small cell lung cancer (NSCLC) patients.
    Swanson, T.
    Dalzell, M. A.
    Small, D.
    MacDonald, N.
    Kreisman, H.
    St-Pierre, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 474S - 474S
  • [24] Exclusions to use of bevacizumab in elderly veterans with advanced non-small cell lung cancer (NSCLC)
    Merza, T.
    Howard, L. M.
    Junagadhwalla, M.
    Gajra, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [25] Efficacy and safety evaluations of anlotinib in patients with advanced non-small cell lung cancer treated with bevacizumab
    Jiang, Fenge
    Li, Junxia
    Kong, Xiangshuo
    Sun, Ping
    Qu, Huajun
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [26] Efficacy and Safety Evaluations of Anlotinib in Patients with Advanced Non-small Cell Lung Cancer Treated with Bevacizumab
    Jiang, F.
    Li, J.
    Kong, X.
    Qu, H.
    Sun, P.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S436 - S436
  • [27] Serum antioxidant levels and survival time in advanced non-small cell lung cancer patients.
    Wirasorn, Kosin
    Hongprabhas, Pranithi
    Pisprasert, Veeradej
    Klarod, Kulthida
    Boonsiri, Patcharee
    CANCER RESEARCH, 2013, 73 (08)
  • [28] Radiogenomics in 332 metastatic non-small cell lung cancer (NSCLC) patients.
    Remon, Jordi
    Faivre, Laura
    Facchinetti, Francesco
    Bluthgen, Maria Virginia
    Pignon, Jean-Pierre
    Planchard, David
    Lacroix, Ludovic
    Besse, Benjamin
    Soria, Jean-Charles
    Caramella, Caroline
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [29] The association between PTEN expression and survival in patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with erlotinib
    Hensing, T. A.
    Fidler, M. J.
    Wong, F.
    Polish, A.
    Watkin, W.
    Basu, S.
    Kaiser-Walters, K. A.
    Pool, M.
    Coon, J.
    Bonomi, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [30] EGFR Status, Risk Factors for Brain Metastases and Overall Survival in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients
    Chowdhury, M.
    Hueniken, K.
    Schmid, S.
    Brown, C.
    Khan, K.
    Walia, P.
    Sabouhanian, A.
    Strom, E.
    Herman, J.
    Xu, W.
    Leighl, N.
    Bradbury, P.
    Sacher, A.
    Shepherd, F.
    Liu, G.
    Shultz, D.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S625 - S626
12345